27 Phase III and 8 Phase II Alzheimer's drugs on track to launch in next 5 years

Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according to a revised Alzheimer's pipeline analysis presented at the Alzheimer's Association International Conference (AAIC) by ResearchersAgainstAlzheimer's (RA2), an UsAgainstAlzheimer's network. The pipeline analysis offers projections for drugs currently in Phase II and Phase III clinical trials and identifies critical milestones in drug development, including estimated trial completion, estimated regulatory filing and estimated launch date.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news